Sclerostin and Bone Health in Chronic Kidney Disease
Summary
Chronic kidney disease (CKD) disrupts mineral homoeostasis and skeletal integrity through a complex syndrome known as CKD‐mineral and bone disorder (CKD‐MBD). Sclerostin, a glycoprotein secreted predominantly by osteocytes, antagonises the canonical Wnt signalling pathway and thereby inhibits osteoblast‐driven bone formation. In CKD, circulating sclerostin concentrations rise progressively as renal clearance declines and osteocytic production adapts to altered phosphate, calcium and parathyroid hormone (PTH) levels. This elevation reflects both reduced renal excretion and a compensatory mechanism to excessive bone turnover. Elevated sclerostin has been linked to changes in bone mineral density (BMD), shifts in bone remodelling markers and an increased propensity for vascular and valvular calcification, which underlie the heightened fracture risk and cardiovascular morbidity observed in advanced CKD. Understanding the dual role of sclerostin in skeletal and vascular tissues is essential for refining therapeutic strategies that target Wnt signalling in patients with renal impairment.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Sclerostin and Bone Health in Chronic Kidney Disease publication trend
The graph below shows the total number of articles in sclerostin and bone health in chronic kidney disease across all publications each year (not limited to Nature Index journals).
Technical terms
Sclerostin: A glycoprotein secreted by osteocytes that inhibits Wnt/β‐catenin signalling and suppresses bone formation.
Wnt signalling: A molecular cascade crucial for osteoblast differentiation and activity, modulated by antagonists such as sclerostin.
CKD‐MBD: A systemic disorder of mineral and bone metabolism due to CKD, manifesting as bone turnover abnormalities, mineralisation defects and vascular calcification.
Bone mineral density (BMD): A measure of bone strength reflecting mineral content, usually assessed by dual‐energy X-ray absorptiometry.
Parathyroid hormone (PTH): A regulator of calcium and phosphate metabolism that influences bone remodelling and is dysregulated in CKD.
References
- Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLOS ONE (2017).
- Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study. BMC Nephrology (2019).
- Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrology (2013).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.